Moxie

In June 2026, Moxie concentrated 65.58% of sales in Flower, where sales fell 77.08% year over year but rose 35.67% month over month, while Edible held 20.17% share with a 22.57% YoY increase and a 54.86% MoM decline. Vapor Pens slipped to 9.49% share with YoY down 79.24% and MoM down 67.12%, and Concentrates at 2.82% saw YoY down 86.47% and MoM down 53.29%; only Pre-Roll, at 1.95% share, grew on both horizons with 112.76% YoY and 45.98% MoM. With overall average price down 34.90% YoY and Flower’s average price at $43.28, the mix now leans on lower-priced Edible and Pre-Roll for volume, implying a defensive tilt toward accessible formats while legacy inhalables contract. The combined effect is a category barbell: Flower rebounds sequentially but remains sharply lower YoY, while Edible and Pre-Roll offset volatility, indicating Moxie is trading depth in inhalables for breadth across value-driven segments.

These shifts reposition Moxie toward mainstream, price-sensitive occasions: a 35.67% MoM lift in Flower alongside a 54.86% MoM pullback in Edible suggests near-term reliance on core Flower replenishment even as the brand tests lower-ticket formats. With Vapor Pens and Concentrates down 67.12% and 53.29% MoM respectively, and down 79.24% and 86.47% YoY, the brand’s historical potency-driven halo is unlikely to anchor share, pushing emphasis onto format accessibility and basket-entry roles signaled by Edible’s 22.57% YoY growth and Pre-Roll’s 112.76% YoY surge. Holding rank 41 in Flower in Ohio while Flower still represents 65.58% of mix indicates a crowded mid-pack stance; the pattern implies Moxie must treat Flower as a traffic driver and use Edible/Pre-Roll as margin stabilizers while selectively pruning underperforming inhalables.